[HTML][HTML] Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens
J Martinez-Sanchez, L Castrillo, D Jerez… - Scientific Reports, 2023 - nature.com
… from participants were spiked ex vivo with apixaban 0 (APIX0), … the antiplatelet effects of
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …
Novel approaches to antiplatelet therapy
P Gresele, S Momi - Biochemical Pharmacology, 2022 - Elsevier
… and has two tyrosines in a conserved sequence known as an … vivo, alone and in combination
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications
… Antithrombotic therapy plays a key role in the treatment of … a prospective, open-label,
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …
[HTML][HTML] Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence
JI Weitz, DJ Angiolillo, T Geisler… - Thrombosis and …, 2020 - thieme-connect.com
… for thrombus formation and targets for oral antithrombotic … effects in in vitro assays and
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …
GTH Congress 2024–68th Annual Meeting of the Society of Thrombosis and Haemostasis Research–Building Bridges in Coagulation
APDC Male, PDDC Ay - Hämostaseologie, 2024 - thieme-connect.com
… , making antithrombotic therapy challenging. Aim of this … and healthy controls by Next
Generation Sequencing. PC levels … 4x higher concentrations with Apixaban and Edoxaban than …
Generation Sequencing. PC levels … 4x higher concentrations with Apixaban and Edoxaban than …
Secondary stroke prevention following embolic stroke of unknown source in the absence of documented atrial fibrillation: a clinical review
ID Kotadia, I Sim, R Mukherjee, D O'Hare… - Journal of the …, 2021 - Am Heart Assoc
… randomized control studies assessing anticoagulation therapy and … Apixaban Recurrent
ischemic/hemorrhagic stroke Study in … A 2‐year study of 295 consecutive patients with ischemic …
ischemic/hemorrhagic stroke Study in … A 2‐year study of 295 consecutive patients with ischemic …
[PDF][PDF] Interactions between aspirin and P2Y12 receptor antagonists in ischaemic heart disease
W Parker - 2020 - etheses.whiterose.ac.uk
… In vitro studies of platelet aggregation confirmed a … Dr Wael Sumaya kindly provided training
in fibrin clot turbidimetry. … coronary intervention and dual antiplatelet therapy. Some months …
in fibrin clot turbidimetry. … coronary intervention and dual antiplatelet therapy. Some months …
The Role of Plasma Extracellular Vesicles and Procoagulant Phospholipid Activity in Venous Thromboembolism
C Ramberg - 2021 - munin.uit.no
… , namely Rivaroxaban, Apixaban and Edoxaban were … , controlled, open label clinical trial
aimed to investigate the … or PE allowed to stop oral anticoagulation treatment by their treating …
aimed to investigate the … or PE allowed to stop oral anticoagulation treatment by their treating …
Platelet Receptor Glycoprotein VI in Ischaemic Stroke
IP Induruwa - 2020 - repository.cam.ac.uk
… would clearly benefit from antiplatelet therapy. However, … of SVD is the lack of in vivo models,
meaning that most of the … High-dose dabigatran and apixaban demonstrated superiority …
meaning that most of the … High-dose dabigatran and apixaban demonstrated superiority …
On the detection of vulnerable plaques in human coronary atherosclerosis
AJ Moss - 2020 - era.ed.ac.uk
… of the HEART Trial sub-study population ...... 45 2.2.2 Dual antiplatelet therapy to Inhibit coronary
… Ex vivo validation of coronary artery specimens using 18F-fluoride demonstrated highly …
… Ex vivo validation of coronary artery specimens using 18F-fluoride demonstrated highly …